Christopher S. Hackett

Oncology · 2019

A researcher in the Science corpus: 1 paper; trusts 4 researchers and is trusted by 0 researchers here, as inferred from the citation graph.

Subfields

Whom Christopher S. Hackett trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

  1. Jang-Hwan Cho
  2. R. Morgan
  3. Levi J. Rupp
  4. Michel Sadelain

Papers from Christopher S. Hackett's perspective

Ordered by how strongly the researchers Christopher S. Hackett trusts endorse each paper. Same corpus, a different order for every researcher.

  1. T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia (Science Translational Medicine)
  2. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia (Science Translational Medicine)
  3. Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia (New England Journal of Medicine)
  4. Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells (Nature Medicine)
  5. Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells (Nature Biotechnology)
  6. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. (Molecular Therapy)
  7. Chimeric antigen receptor T-cell therapy — assessment and management of toxicities (Nature Reviews Clinical Oncology)
  8. Therapeutic T cell engineering (Nature)
  9. Structural design of engineered costimulation determines tumor rejection kinetics and persistence of CAR T cells (Cancer Cell)
  10. Remote control of therapeutic T cells through a small molecule-gated chimeric receptor (Science)

Their papers